Literature DB >> 27988801

Measuring the actual I-131 thyroid uptake curve with a collar detector system: a feasibility study.

Peter Brinks1, Koen Van Gils2, Ellen Kranenborg3, Jules Lavalaye3, Dennis B M Dickerscheid2, Jan B A Habraken2.   

Abstract

Radionuclide therapy using I-131 is commonly used for the treatment of benign thyroid diseases. The therapeutic dose to be administered is calculated based on the type of disease, the volume of the thyroid, and the measured uptake percentage. This methodology assumes a similar biological half-life of iodine, whereas in reality a large variation in biological half-life is observed. More knowledge about the actual biological half-life of iodine for individual patients will improve the quantification of the delivered radiation dose during radioiodine therapy and could aid the evaluation of the success of the therapy. In this feasibility study we used a novel measurement device [Collar Therapy Indicator (CoTI)] to measure the uptake curve of patients undergoing I-131 radioiodine therapy. The CoTI device is a light-weight wearable device that contains two independent gamma radiation detectors that are placed in a collar. By comparing results of thyroid uptake measurements with results obtained with a gamma camera, the precision of the system is demonstrated. Additionally, for three patients the uptake curve is measured during 48 h of admission in the hospital. The presented results demonstrate the feasibility of the new measurement device to measure the uptake curve during radioiodine therapy.

Entities:  

Keywords:  Dosimetry; I-131; Iodine; Pharmacokinetics; Radionuclide therapy; Thyroid

Mesh:

Substances:

Year:  2016        PMID: 27988801     DOI: 10.1007/s00259-016-3595-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  9 in total

1.  EANM procedure guidelines for therapy of benign thyroid disease.

Authors:  Marcel P M Stokkel; Daria Handkiewicz Junak; Michael Lassmann; Markus Dietlein; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-13       Impact factor: 9.236

2.  EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases.

Authors:  Heribert Hänscheid; Cristina Canzi; Wolfgang Eschner; Glenn Flux; Markus Luster; Lidia Strigari; Michael Lassmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-11       Impact factor: 9.236

Review 3.  Nuclear medicine in the diagnosis of benign thyroid diseases.

Authors:  Rafał Czepczyński
Journal:  Nucl Med Rev Cent East Eur       Date:  2012-08-29

4.  Radiation dose assessment in radioiodine therapy. 2. Practical implementation using quantitative scanning and PET, with initial results on thyroid carcinoma.

Authors:  M A Flower; T Schlesinger; P J Hinton; I Adam; A M Masoomi; M A Elbelli; R J Ott; V R McCready; C L Harmer
Journal:  Radiother Oncol       Date:  1989-08       Impact factor: 6.280

5.  Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.

Authors:  G E Berg; A M Michanek; E C Holmberg; M Fink
Journal:  J Nucl Med       Date:  1996-02       Impact factor: 10.057

6.  Measurement of iodine-123 thyroid uptake using a gamma camera with LEAP collimator.

Authors:  R S Benjamin; A Amro; M I El-Desouki
Journal:  J Nucl Med Technol       Date:  1999-09

7.  Determining thyroid (131)I effective half-life for the treatment planning of Graves' disease.

Authors:  José Willegaignon; Marcelo T Sapienza; George Barbério Coura Filho; Antonio C Traino; Carlos A Buchpiguel
Journal:  Med Phys       Date:  2013-02       Impact factor: 4.071

8.  Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?

Authors:  Carsten Kobe; Wolfgang Eschner; Markus Wild; Ilka Rahlff; Ferdinand Sudbrock; Matthias Schmidt; Markus Dietlein; Harald Schicha
Journal:  Nucl Med Commun       Date:  2010-03       Impact factor: 1.690

9.  Radioiodine and thyroid disease: the beginning.

Authors:  D V Becker; C T Sawin
Journal:  Semin Nucl Med       Date:  1996-07       Impact factor: 4.446

  9 in total
  2 in total

1.  In vitro evaluation of an iodine radionuclide dosimeter (IRD) for continuous patient monitoring.

Authors:  Sanaz Hariri Tabrizi; Meysam Ramezani; Seyed Amir Hossein Feghhi; Parham Geramifar
Journal:  Med Biol Eng Comput       Date:  2020-01-28       Impact factor: 2.602

2.  Real-time quantitation of thyroidal radioiodine uptake in thyroid disease with monitoring by a collar detection device.

Authors:  Prasanna Santhanam; Lilja Solnes; Tanmay Nath; Jean-Paul Roussin; David Gray; Eric Frey; George Sgouros; Paul W Ladenson
Journal:  Sci Rep       Date:  2021-09-16       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.